~~<i id='16A6F1B545'><strike id='16A6F1B545'><tt id='16A6F1B545'><pre id='16A6F1B545'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-29 02:16:41 Page View：7795

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Alzheimer's drugs heat up race for early detection blood tests
Next article： At least 13 dead in Texas as scorching temps continue

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Judge rejects Trump's counterclaim against E. Jean Carroll

2:07E.JeanCarrollreactsassheexitstheManhattanFederalCourtfollowingtheverdictinthecivilrapeaccusation

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

More regulation could be coming for drug ads

AdobeWASHINGTON—Governmentregulatorsmaysoondecidewhethertocrackdownondistractingvisualsintelevisiond